PowerPoint - Palliative.info

Considerations For
Opioid Prescribing in
Palliative Care
Mike Harlos MD, CCFP, FCFP
Professor and Section Head, Palliative Medicine, University of Manitoba
Medical Director, Adult and Pediatric Palliative Care, WRHA
Clinical Lead, Canadian Virtual Hospice
The presenter has no conflict
of interest to disclose
• to review the role of of opioids in palliative care
• to review considerations related to opioid
prescribing in managing pain and dyspnea in
palliative care
• to consider some of the ethical concerns
sometimes associated with opioid prescribing in
patients at end of life
• Opiates: a group of naturally occurring compounds derived
from the juice of the poppy Papaver somniferum
- morphine is the classic opiate in clinical use
• Opioids: refers to these, as well as semisynthetic (e.g.
hydromorphone) and synthetic (fentanyl, methadone)
drugs that act on opioid receptors (mu, delta, kappa)
• primary uses in palliative care are management of pain
and dyspnea
Strong Opioids
• most commonly use morphine, hydromorphone,
fentanyl, methadone, oxycodone
• codeine tends not to be used
- pro-drug of morphine – might as well use lowdose morphine
- high variability in metabolizing to morphine
• usually reasonable to start with morphine, unless
significant renal impairment
Approach To Pain Control in Palliative Care
1. Thorough assessment
• History – including detailed description of pain; psychosocial,
spiritual, & cultural context; concerns about what the pain
means; medication history
• Physical Examination – don’t forget neuro exam
2. Pause here - discuss with patient/family the goals of care,
hopes, expectations, anticipated course of illness. This will
influence consideration of investigations and interventions
3. Investigations – X-Ray, CT, MRI, etc - if they will affect approach
to care
4. Treatments – pharmacological and non-pharmacological;
interventional analgesia (e.g. spinal); RadTx
5. Ongoing reassessment and review of options, goals,
expectations, etc.
Considerations When Starting An Opioid
• are opioids appropriate for the symptom, or might other
measures be added? (adjuvant analgesics, RadTx)
- not all pain syndromes are expected to respond fully to
opioids – specifically neuropathic pain
• should you start with prn dosing or regular dosing?
- depends on the context
- prn reasonable for occasional pain, or when the pattern
is unknown or erratic and baseline opioid requirements
need to be determined
- regular dosing should be provided for pain that is
consistent, progressive and not expected to resolve
- you end up using more opioids chasing pain than
remaining ahead of it
Considerations When Starting An Opioid
• what route(s) of administration are available, and is that
expected to change?
- e.g. recurrent bowel obstruction, progressive dysphagia
• are there circumstances that warrant a conservative
- pediatrics
- frail elderly
- starting opioids for dyspnea in an end-stage COPD
patient (unless severe distress compels an aggressive
approach, in which case you remain with patient until
“Start Low, Go Slow”
• If you start cautiously with an anticipated
ineffective dose, be prepared to titrate up quickly
• “prepared” means attentive, proactive, vigilant,
available (i.e. don’t assume things are fine if
nobody calls you)
• “first-dose survival test”
• Reassess early (perhaps later that day even),
and consider increasing to a more “usual” dose
Some Overarching Principles
• doses proportionate to the degree of distress are safe
• anticipate and preempt predictable (“incident”) pain
• dose increases 10% - 100%, depending on the context;
usually should achieve steady state (5 half-lives) before
increasing dose
• IV, subcut administration bypass first-pass metabolism
in the liver, and doses usually ½ the po dose
• short-acting opioids (typically morphine,
hydromorphone) should be used during dose titration
and when pain is unstable
Switching Between Short-Acting And LongActing Preparations Of The Same Opioid
• usually simply add up the total daily opioid dose, and
divide by the # doses per 24 hrs
• e.g.: MS-Contin® 100 mg tid
= 300 mg/day
= 50 mg q4h of short-acting prep
• e.g.: hydromorphone 8 mg q4h
= 48 mg/day
= 16 mg tid of long-acting hydromorphone prep
Considerations In Opioid Selection
po, SL*, subcut, IV, IM, pr
• metabolite (M3G, M6G)
accumulation in renal insuff
• metabolite accumulation (H3G)
in renal insuff
po, SL*, subcut, IV, IM, pr,
intranasal (IN)*
• ? better tolerated in elderly than
morphine (no literature)
• parent drug may accumulate in
renal insuff – need to watch
IV, subcut, SL*, IN*,
• no active metabolites; a
preferred choice in renal insuff
po, SL*, IV**
• requires exemption from Health
Canada / CPSM
• no active metabolites; a
preferred choice in renal insuff
* off-label use
** must be obtained from outside Canada through Health Canada
Determining The Correct Opioid Dose
Somewhere in here
i.e. the opioids are titrated proportionately to achieve
the desired effect
Sample Adult Doses
Usual Adult Starting
Potential Starting Doses In Frail
Elderly or Advanced Resp
5 – 10 mg q4h
1 – 2 mg q6h
2.5 – 5 mg q4h
0.5 – 1 mg q6h
1 mg q4h
0.25 – 0.5 mg q6h
0.5 mg q4h
0.125 – 0.25 mg q6h
5 mg q6h
It would be extremely unusual to
start a frail elderly or resp patient
on oxycodone rather than
morphine or hydromorphone
Opioid Conversions
• conversions tables usually based on single-dose
studies in opioid-naïve patients (not tolerant to opioids)
• with ongoing exposure to an opioid, tolerance develops
• when opioids are switched, this tolerance is not fully
crossed over to an alternative opioid
= Incomplete Cross-Tolerance
• cannot use conversion tables to determine the dose of
an alternative opioid without considering the clinical
• might consider decreasing the calculated dose by 50%,
but even that depends on the situation
Considerations In Switching Opioids
• If you are switching because of adverse effects such as
nausea, and the baseline pain control is:
- poor: don’t usually decrease the calculated dose – the
patient needs an opioid increase
- good: likely should decrease the calculated dose by 50%
due to incomplete cross-tolerance
• When switching opioids in any high dose situation, be very
careful about the potential risk caused by incomplete crosstolerance
• in suspected opioid-induced neurotoxicity with opioid-induced
hyperalgesia, don’t even try to calculate an alternative opioid.
- discontinue the offending opioid, and use prn dosing of a
suitable alternative to determine opioid needs
Basic Conversions – Starting Points For Consideration
Drug Conversion
5 mg morphine = 1 mg
hydromorphone is about 5 times more
potent than morphine
1.5 mg morphine = 1 mg
oxycodone is about 1.5 times more
potent than morphine
Methadone to anything
Context dependent
Transdermal fentanyl
Use drug monograph
Conversion Examples
• 65 yo man with metastatic lung CA on morphine 30 mg
q4h, good pain control, nauseated with morphine,
switching to hydromorphone
- 30 mg morphine ≃ 6 mg hydromorphone
- reduce due to incomplete cross-tolerance
- 3 or 4 mg hydromorphone q4h would be a reasonable
initial conversion
• same patient, but the context is one of suboptimal pain
- reasonable to start with hydromorphone 6 mg q4h
1. ⬇︎current dose 10 - 30% while beginning new opioid at opioidnaïve dose or at the lowest available dose for the formulation.
2. Slowly ⬇︎ original total daily opioid dose by about 10 - 25% per
week while ⬆︎ new daily opioid dose by about 10 - 20% based on
clinical need and safety. In most instances, the complete switch
can occur within 3 - 4 weeks.
3. Provide sufficient immediate-release opioid throughout the
rotation to prevent withdrawal and/or increased pain if the dosing
changes prove insufficient.
Breakthrough Doses
• breakthrough doses are usually 10-20% of total daily
dose, or equal to the q4h dose
• the correct dose is the one that works – this may vary for
an individual patient, and might be substantially different
between patients
• prn interval for breakthroughs should reflect
pharmacology –i.e. when is it reasonable to repeat?
(enteral 1 hr; subcut 30 min; IV 10-15 min; transmucosal
10-15 min)
• if you want to limit the # breakthrough doses due to
safety concerns, do so by limiting the # doses over a
period, but keep the reasonable interval
Stacking Doses
Breakthrough Dose Examples
• Patient on 100 mg tid MS-Contin® = 300 mg/day
Breakthrough dose should be short-acting morphine 30
mg po q1h prn
• Patient on 8 mg hydromorphone q4h subcut
Breakthrough dose should be 8 mg subcut q30 min prn
(sometimes we end up writing q1h prn, as sometimes the
facility is not comfortable with a short interval)
Transdermal Fentanyl
• not for use in opioid-naïve patients
• not for use in unstable pain
• particularly useful when pain control is stable in an
opioid-tolerant patient and:
- oral route is compromised, or vulnerable (e.g. recurrent
bowel obstruction, head and neck CA, ALS, etc)
- simplifying a medication regimen in a non-compliant or
confused patient (may need to put “out of sight” – e.g.
- simplify a medication regimen for other reasons –
traveling, facilitating medication storage or diversion
issues, less complex for family caregivers
Transdermal Fentanyl
• approx 100 x more potent that morphine – i.e.
50 mcg fentanyl (= 0.05 mg fentanyl) ≃ 0.05 x 100
= 5 mg morphine
• titrate no more often than q3d (each patch change)
• “the gift that keeps giving” – it takes approx 17 hrs for
serum levels to reduce by 50% once the patch is
• patients may put it where it hurts – same with heating
pads and hot water bottles
Changes In Plasma Fentanyl Concentration
With Heat Application
• plasma fentanyl concentrations significantly lower in
cachectic patients
• impaired transdermal fentanyl absorption in patients with
cancer-related cachexia
• seems to be an issue of absorption
Converting To Transdermal Fentanyl
As Per Duragesic ® Monograph
Opioid Breakthrough Doses For Patients
Receiving Transdermal Fentanyl
Opioid Side Effects
• Constipation – need proactive laxative use
• Nausea/vomiting – consider treating with dopamine
antagonists and/or prokinetics (metoclopramide,
domperidone, prochlorperazine [Stemetil], haloperidol)
• Urinary retention
• Itch/rash – worse in children; may need low-dose naloxone
infusion. May try antihistamines, however not great success
• Dry mouth
• Respiratory depression – uncommon when titrated in
proportion to symptom
• Drug interactions – additive sedation, enzyme induction or
• Neurotoxicity (OIN): delirium, myoclonus, seizures
Opioid-Induced Constipation
• assume that someone prescribed opioids will become
• “The hand that writes the opioid prescription should write the
laxative prescription” (Dame Cicely Saunders)
• Librach SL et al; J Pain Symptom Manage. 2010;40(5):761-73) –
Consensus recommendations:
1. Osmotic laxatives, lactulose, and PEG are supported by
Grade A evidence and are recommended in the appropriate
2. Use of docusates is not recommended.
3. Use of mineral oil is not recommended.
4. Stimulants such as senna base laxatives and bisacodyl can
be used despite the insufficient evidence of efficacy.
5. If constipation persists, an enema or suppository may be
Spectrum of Opioid-Induced Neurotoxicity
Mild myoclonus
(eg. with sleeping)
Severe myoclonus
as Pain
as Disease-Related Pain
“Allergic” To Morphine
• true allergy to an opioid is very uncommon
• adverse effects such as delirium, pruritus often labeled as
• morphine and to some degree hydromorphone can cause
histamine release from mast cells, with urticaria and
pruritus – not an immune-mediated phenomenon, not an
• fentanyl tends not to cause histamine release
• if pain is mild to moderate, might consider tramadol
• if a strong opioid is needed, it would be reasonable to try
an opioid from a different class
Opioids And Dyspnea
Johnson MJ, Abernethy AP, and Currow DC. Gaps in the evidence base of
opioids for refractory breathlessness. A future work plan? J Pain Symptom
Manage. United States; 2012;43(3):614-24.
• may reduce overall oxygen demand
• “The administration of sedatives (midazolam and morphine) has been
associated with decreases in oxygen demand and the attenuation of the
cardiopulmonary response associated with increased work of breathing”
• see also: Endoh H et al; Effects of naloxone and morphine on acute
hypoxic survival in mice. Crit Care Med; 1999;27(9):1929-33
significantly lower oxygen consumption and improved survival in
morphine treated rats subjected to acute hypoxic hypoxia
Common Concerns About Aggressive Use
of Opioids at End-Of-Life
• How do you know that the aggressive use
of opioids for dyspnea doesn't actually bring
about or speed up the patient's death?
• “I gave the last dose of morphine and he
died a few minutes later… did the
medication cause the death?”
1. Literature: the literature supports that opioids
administered in doses proportionate to the degree
of distress do not hasten death and may in fact
delay death
2. Clinical context: breathing patterns usually seen in
progression towards dying (clusters with apnea,
irreg. pattern) vs. opioid effects (progressive
slowing, regular breathing; pinpoint pupils)
3. Medication history: usually “the last dose” is the
same as those given throughout recent hours/days,
and was well tolerated
A normal physiological phenomenon in
which increasing doses are required to
produce the same effect
Inturrisi C, Hanks G. Oxford Textbook of Palliative Medicine 1993: Chapter 4.2.3
A normal physiological phenomenon in
which a withdrawal syndrome occurs when
an opioid is abruptly discontinued or an
opioid antagonist is administered
Inturrisi C, Hanks G. Oxford Textbook of Palliative Medicine 1993: Chapter 4.2.3
A pattern of drug use characterized by a
continued craving for an opioid which is
manifest as compulsive drug-seeking
behaviour leading to an overwhelming
involvement in the use and procurement of
the drug
Inturrisi C, Hanks G. Oxford Textbook of Palliative Medicine 1993: Chapter 4.2.3

similar documents